Ardelyx Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
34,435.00
107,286.00
107,004.00
200,823.00
133,976.00
168,089
Total Accounts Receivable
6,436.00
2,584.00
-
-
10,796.00
5,085
Other Current Assets
965.00
1,209.00
5,027.00
3,169.00
4,940.00
3,197
Total Current Assets
41,836.00
111,079.00
112,031.00
203,992.00
149,712.00
176,371
Net Property, Plant & Equipment
530.00
2,131.00
4,711.00
8,991.00
8,032.00
5,611
Total Investments and Advances
180.00
100.00
100.00
-
-
-
Other Assets
358.00
104.00
104.00
148.00
159.00
1,350
Total Assets
42,904.00
113,414.00
116,946.00
213,131.00
157,903.00
183,332
Accounts Payable
2,284.00
3,129.00
2,777.00
5,635.00
3,933.00
Other Current Liabilities
14,855.00
18,407.00
4,946.00
13,566.00
13,938.00
Total Current Liabilities
17,139.00
21,536.00
7,723.00
19,201.00
17,871.00
Other Liabilities
33,089.00
31,196.00
322.00
779.00
720.00
Total Liabilities
50,228.00
52,732.00
8,045.00
19,980.00
18,591.00
Common Equity (Total)
63,479.00
60,682.00
108,901.00
193,151.00
139,312.00
Total Shareholders' Equity
63,479.00
60,682.00
108,901.00
193,151.00
139,312.00
Total Equity
63,479.00
60,682.00
108,901.00
193,151.00
139,312.00
Liabilities & Shareholders' Equity
42,904.00
113,414.00
116,946.00
213,131.00
157,903.00
Non-Equity Reserves
56,155.00
-
-
-
-

About Ardelyx

View Profile
Address
34175 Ardenwood Boulevard
Fremont California 94555
United States
Employees -
Website http://www.ardelyx.com
Updated 07/08/2019
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicine for the treatment of renal diseases. It also focuses on the development of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development.